Biosensors

Biosensors: the stock is down 3.4% at $1.135, extending its downward drift since releasing its FYMar12 results. Strangely, the results were in line with Street expectations, and guidance remained fairly positive. The are no further corporate updates from the company, nor any significant competing technology breakthrough to highlight. Technically, momentum remains weak for the stock, with RSI sliding and Stochastics still not showing signs of a positive reversal. There may be support at ~$1.10 (coincides wtih double bottom made in Sep '11 and May '12). Resistance is at $1.20.